We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+0.86%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
+$121M
Cap. Flow
+$179M
Cap. Flow %
11.83%
Top 10 Hldgs %
46.72%
Holding
103
New
28
Increased
19
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$70.7M
2
UNH icon
UnitedHealth
UNH
+$33M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.5M
4
ELV icon
Elevance Health
ELV
+$28.2M
5
JBIO
Jade Biosciences
JBIO
+$27.1M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$22.4M
2
HOLX
Hologic
HOLX
+$18.7M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$17.7M
4
MRUS
Merus
MRUS
+$16.3M
5
INSM icon
Insmed
INSM
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.75%
2 Consumer Staples 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
101
Sarepta Therapeutics
SRPT
$1.73B
– –
-58,000
Closed -$3.7M
TEVA icon
102
Teva Pharmaceuticals
TEVA
$40.1B
– –
-450,500
Closed -$6.92M
XBI icon
103
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.92B
– –
-1,400,000
Closed -$114M
1 2 3 4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Soleus Capital Management held 103 positions worth $1.51B, up 8.7% from $1.39B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Soleus Capital Management deployed $179M of net new capital in Q2 2025, opening 28 new positions and adding to 19 existing holdings. Its largest new stake was UnitedHealth: 86,250 shares worth $26.9M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was TG Therapeutics, an estimated $22.4M trimmed.

  • Soleus Capital Management's largest Q2 2025 buy was UnitedHealth: 86,250 shares worth $26.9M.
  • Soleus Capital Management added most to Krystal Biotech in Q2 2025, an estimated $70.7M increase.
  • Soleus Capital Management's biggest Q2 2025 reduction was TG Therapeutics, cutting an estimated $22.4M.
  • Soleus Capital Management fully exited Hologic in Q2 2025, selling an estimated $18.7M.
  • Soleus Capital Management's ten largest holdings make up 47% of its $1.51B portfolio in Q2 2025.
  • Soleus Capital Management opened 28 new positions and closed 8 in Q2 2025.
  • Soleus Capital Management's portfolio value rose 8.7% quarter-over-quarter to $1.51B.

Based on Soleus Capital Management's 13F filing for Q2 2025, filed 15 Aug 2025.